Caxton Corp grew its holdings in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 76.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,994 shares of the biotechnology company’s stock after buying an additional 7,818 shares during the quarter. Aclaris Therapeutics comprises 0.5% of Caxton Corp’s investment portfolio, making the stock its 12th biggest holding. Caxton Corp owned 0.06% of Aclaris Therapeutics worth $444,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. boosted its holdings in Aclaris Therapeutics by 28.4% in the fourth quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock valued at $54,129,000 after acquiring an additional 485,146 shares during the last quarter. Eagle Asset Management Inc. lifted its stake in shares of Aclaris Therapeutics by 1.7% during the third quarter. Eagle Asset Management Inc. now owns 1,380,549 shares of the biotechnology company’s stock worth $36,446,000 after purchasing an additional 22,576 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Aclaris Therapeutics by 3.5% during the third quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock worth $23,030,000 after purchasing an additional 29,896 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Aclaris Therapeutics by 14.2% during the second quarter. Vanguard Group Inc. now owns 812,318 shares of the biotechnology company’s stock worth $22,029,000 after purchasing an additional 100,799 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in shares of Aclaris Therapeutics by 73.8% during the fourth quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock worth $12,908,000 after purchasing an additional 222,254 shares in the last quarter. 92.40% of the stock is owned by institutional investors and hedge funds.
Shares of Aclaris Therapeutics Inc (ACRS) traded down $0.56 during trading hours on Thursday, reaching $19.10. 120,601 shares of the company’s stock traded hands, compared to its average volume of 332,090. Aclaris Therapeutics Inc has a 52 week low of $18.46 and a 52 week high of $33.10.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.80 million. equities research analysts anticipate that Aclaris Therapeutics Inc will post -4.11 earnings per share for the current year.
Several analysts recently weighed in on the company. Guggenheim assumed coverage on Aclaris Therapeutics in a report on Thursday, February 8th. They issued a “buy” rating and a $53.00 price objective for the company. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a report on Friday, December 15th. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 19th. BidaskClub downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Finally, Leerink Swann cut their target price on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Aclaris Therapeutics presently has an average rating of “Hold” and an average price target of $43.83.
TRADEMARK VIOLATION NOTICE: “Caxton Corp Has $444,000 Holdings in Aclaris Therapeutics Inc (ACRS)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/03/15/caxton-corp-buys-7818-shares-of-aclaris-therapeutics-inc-acrs.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.